Stem Cell Transplantation

Christopher Hourigan, EHA 2019 – Allogenic Transplantation for AML

We are joined by Christopher Hourigan at the EHA annual meeting to discuss his presentation on the impact of conditioning intensity of allogenic transplantation for acute myeloid leukaemia with genomic evidence of residual disease. Questions 1. What different conditioning regimens are typically used before allogeneic haematopoietic stem cell transplantation (HSCT)? (0:05) 2. What factors affect […]

Bmi1 – A Path to Targeting Cancer Stem Cells

European Oncology & Haematology, 2017;13(2):147–51 DOI: https://doi.org/10.17925/EOH.2017.13.02.147

Since the discovery of the Polycomb group (PcG) gene family in Drosophila as repressors of homeotic (HOX) genes, PcG proteins have been implicated in a range of processes from chromosome X inactivation to stem cell plasticity and differentiation. PcG proteins execute their function through transcriptional repression of the promoter region of a target gene. Although […]

Plasmacytic Post-transplant Lymphoproliferative Disorder – Case Report

European Oncology & Haematology, 2017;13(1):80–2 DOI: https://doi.org/10.17925/EOH.2017.13.01.80

Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT). Most of the PTLDs originate from B-cells. Overall, 60–80% of PTLDs are associated with Epstein-Barr virus (EBV); this can vary depending on PTLD type and time of onset after HSCT.1,2 The majority of the general population is infected by EBV during their […]

Targeting Cancer Stem Cells—A Renewed Therapeutic Paradigm

Oncology & Hematology Review, 2017;13(1):45–55 DOI: https://doi.org/10.17925/OHR.2017.13.01.45

Despite substantial advances in cancer diagnosis and treatment, the long-term survival rate for many cancer patients remains dismal.1 More than 90% of cancer-related mortality is ascribed to disease resurgence months or years after adjuvant therapy, either in the form of local recurrence or in the form of metastatic spread, which are typically refractory to existing […]

How to Find the Optimal Mobilisation Strategy – Impact, Challenges and Solutions

European Oncology & Haematology, 2016;12(2):87–92 DOI: https://doi.org/10.17925/EOH.2016.12.02.87

Autologous haematopoietic stem-cell transplantation (HSCT) is widely employed in haematological malignancies including multiple myeloma (MM),1 Hodgkin and non-Hodgkin lymphoma (HL and NHL)2–5 and acute myeloid leukaemia (AML).6,7 High-dose chemotherapy is an effective treatment strategy in numerous malignant conditions, however, it requires the subsequent use of autologous HSCT in order to restore bone marrow function, mostly […]

The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML?

European Oncology & Haematology, 2015;11(1):30–1 DOI: https://doi.org/10.17925/EOH.2015.11.01.30

As the development of BCR-ABL1 targeting treatments has continued, patients with chronic phase chronic myeloid leukaemia (CML‑CP) were shown to have similar survival rates in all age groups to that of general population in the era of tyrosine kinase inhibitors (TKIs).1 First, imatinib and subsequently the second-generation TKIs (2GTKIs) (nilotinib and dasatinib) revolutionised the treatment […]

Chronic Myeloid Leukaemia – The Choice of Therapy and Future Perspectives

European Oncology & Haematology, 2015;11(1):25–9 DOI: https://doi.org/10.17925/EOH.2015.11.01.25

The overwhelming majority of patients diagnosed with chronic phase chronic myeloid leukaemia (CP-CML) can achieve long-term survival with a good quality of life. In a recent review, it has been suggested that CML patients responsive to tyrosine kinase inhibitors (TKIs) might become a chronic disease, such as diabetes or hypertension, requiring maintenance treatment.1 If we […]

Defibrotide – A New Treatment Approach for Severe Veno-occlusive Disease

European Oncology & Haematology, 2015;11(1):11–4 DOI: https://doi.org/10.17925/EOH.2015.11.01.11

Haematopoietic stem cell transplantation (HSCT) has become the standard of care for many haematological malignancies, selected solid tumours and some non-malignant disorders.1 However, it can be associated with serious complications, in particular, veno-occlusive disease (VOD). Approximately 14 % of HSCT patients develop VOD, although incidences of up to 60 % have been reported.2,3 Incidence is […]

Clinical Utility of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Agents

European Oncology & Haematology, 2012;8(4):254-260

Abstract The adoption of high dose therapy and autologous stem cell rescue (ASCT) for multiple myeloma (MM) in the 1990s heralded a significant advance in outcomes for this incurable plasma cell malignancy. However, over the last decade, the availability of novel agents has once again radically altered the landscape of MM therapy and previously unachievable […]